CO6660456A2 - Agente preventivo o terpéutico contra la fibrosis - Google Patents
Agente preventivo o terpéutico contra la fibrosisInfo
- Publication number
- CO6660456A2 CO6660456A2 CO13094380A CO13094380A CO6660456A2 CO 6660456 A2 CO6660456 A2 CO 6660456A2 CO 13094380 A CO13094380 A CO 13094380A CO 13094380 A CO13094380 A CO 13094380A CO 6660456 A2 CO6660456 A2 CO 6660456A2
- Authority
- CO
- Colombia
- Prior art keywords
- bases
- positions
- preventive
- therapeutic agent
- agent against
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
siARN eficaz para el tratamiento de la fibrosis y un producto farmacéutico, que contiene siARN. Un siARN que tiene una longitud completa de 30 o menos nucleótidos y que se dirige a una secuencia que consiste de 17 a 23 bases consecutivas seleccionadas del grupo que consiste en bases en las posiciones 1285 a 1318, bases en las posiciones 1398 a 1418, bases en las posiciones 1434 a 1463, bases en las posiciones 1548 a 1579, bases en las posiciones 1606 a 1628, bases en las posiciones 1700 a 1726, bases en las posiciones 1778 a 1798, bases en las posiciones 1806 a 1826 y bases en las posiciones 1887 a 1907 de SEQ ID NO: 1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010231946 | 2010-10-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6660456A2 true CO6660456A2 (es) | 2013-04-30 |
Family
ID=45938402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO13094380A CO6660456A2 (es) | 2010-10-14 | 2013-04-11 | Agente preventivo o terpéutico contra la fibrosis |
Country Status (30)
| Country | Link |
|---|---|
| US (6) | US8772262B2 (es) |
| EP (2) | EP2628798B1 (es) |
| JP (4) | JP6022940B2 (es) |
| KR (2) | KR101853799B1 (es) |
| CN (2) | CN106086022B (es) |
| AR (1) | AR083445A1 (es) |
| AU (1) | AU2011314653B2 (es) |
| BR (1) | BR112013006541A2 (es) |
| CA (1) | CA2813163C (es) |
| CO (1) | CO6660456A2 (es) |
| CY (1) | CY1121945T1 (es) |
| DK (1) | DK2628798T3 (es) |
| ES (1) | ES2720135T3 (es) |
| HK (1) | HK1184189A1 (es) |
| HR (1) | HRP20190722T1 (es) |
| HU (1) | HUE043891T2 (es) |
| IL (2) | IL224791A (es) |
| LT (1) | LT2628798T (es) |
| MX (1) | MX348555B (es) |
| MY (1) | MY165964A (es) |
| NZ (2) | NZ609440A (es) |
| PL (1) | PL2628798T3 (es) |
| PT (1) | PT2628798T (es) |
| RU (1) | RU2583290C2 (es) |
| SG (3) | SG189245A1 (es) |
| SI (1) | SI2628798T1 (es) |
| TR (1) | TR201905060T4 (es) |
| TW (2) | TWI679023B (es) |
| WO (1) | WO2012050181A1 (es) |
| ZA (1) | ZA201301279B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR083445A1 (es) | 2010-10-14 | 2013-02-27 | Univ Mie | siARN CONTRA LA FIBROSIS |
| WO2015093495A1 (ja) * | 2013-12-16 | 2015-06-25 | 株式会社ボナック | ＴＧＦ－β１遺伝子発現制御のための一本鎖核酸分子 |
| JP6726105B2 (ja) | 2014-12-15 | 2020-07-22 | 株式会社ボナック | ＴＧＦ−β１発現抑制のための一本鎖核酸分子 |
| WO2017043490A1 (ja) * | 2015-09-07 | 2017-03-16 | 協和発酵バイオ株式会社 | 自然免疫誘導効果が増強した二重鎖リボ核酸 |
| WO2017073767A1 (ja) * | 2015-10-30 | 2017-05-04 | 株式会社ボナック | ＴＧＦ－β１遺伝子の発現を抑制する一本鎖核酸分子を安定に含有する組成物 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
| US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| WO2003035869A1 (de) | 2001-10-26 | 2003-05-01 | Ribopharma Ag | Verwendung einer doppelsträngigen ribonukleinsäure zur gezielten hemmung der expression eines vorgegebenen zielgens |
| US7767802B2 (en) | 2001-01-09 | 2010-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
| US7423142B2 (en) | 2001-01-09 | 2008-09-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
| US8546143B2 (en) | 2001-01-09 | 2013-10-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| US7745418B2 (en) | 2001-10-12 | 2010-06-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting viral replication |
| DE10163098B4 (de) | 2001-10-12 | 2005-06-02 | Alnylam Europe Ag | Verfahren zur Hemmung der Replikation von Viren |
| DE10230997A1 (de) | 2001-10-26 | 2003-07-17 | Ribopharma Ag | Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels |
| JP2005512976A (ja) | 2001-10-26 | 2005-05-12 | リボファーマ アーゲー | Ｒｎａ干渉により線維化疾患を処置するための医薬 |
| WO2003035876A1 (de) | 2001-10-26 | 2003-05-01 | Ribopharma Ag | Verwendung einer doppelsträngigen ribonukleinsäure zur behandlung einer infektion mit einem (+)-strang-rna-virus |
| US20040121348A1 (en) | 2001-10-26 | 2004-06-24 | Ribopharma Ag | Compositions and methods for treating pancreatic cancer |
| ATE536408T1 (de) * | 2003-04-02 | 2011-12-15 | Dharmacon Inc | Modifizierte polynukleotide zur verwendung bei rna-interferenz |
| US7668257B2 (en) * | 2003-10-01 | 2010-02-23 | Samsung Electronics Co., Ltd. | Transmissions with reduced code rate in 8VSB digital television |
| KR101147147B1 (ko) | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드 |
| JP2007119396A (ja) | 2005-10-28 | 2007-05-17 | Hosokawa Funtai Gijutsu Kenkyusho:Kk | 核酸化合物封入ナノ粒子を含む経肺投与用医薬製剤 |
| EP1951263A4 (en) | 2005-11-21 | 2009-11-18 | Johnson & Johnson Res Pty Ltd | MULTITARGETING DISTURBING RNAS WITH TWO ACTIVE STRANDS AND DESIGN AND APPLICATION METHODS |
| EP1976986A2 (en) | 2005-12-30 | 2008-10-08 | Intradigm Corporation | Sirna compositions promoting scar-free wound healing of skin and methods for wound treatment |
| EP1993611A4 (en) | 2006-03-16 | 2013-05-22 | Alnylam Pharmaceuticals Inc | RNAi MODULATION OF TGF-BETA AND THERAPEUTIC USES |
| EP2126082A1 (en) | 2007-03-02 | 2009-12-02 | MDRNA, Inc. | Nucleic acid compounds for inhibiting bcl2 gene expression and uses thereof |
| WO2008109548A2 (en) | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting tgfb gene expression and uses thereof |
| US20100055782A1 (en) | 2007-03-02 | 2010-03-04 | Mdrna, Inc. | Nucleic acid compounds for inhibiting myc gene expression and uses thereof |
| WO2008109357A1 (en) | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting apob gene expression and uses thereof |
| WO2008109373A1 (en) | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting erbb gene expression and uses thereof |
| CA2679339A1 (en) | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting wnt gene expression and uses thereof |
| CA2679342A1 (en) | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting hif1a gene expression and uses thereof |
| US20100105134A1 (en) * | 2007-03-02 | 2010-04-29 | Mdrna, Inc. | Nucleic acid compounds for inhibiting gene expression and uses thereof |
| WO2008109362A1 (en) | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting vegf gene expression and uses thereof |
| WO2008109516A2 (en) | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting ras gene expression and uses thereof |
| CA2679387A1 (en) | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting akt gene expression and uses thereof |
| WO2008109361A1 (en) | 2007-03-02 | 2008-09-12 | Mdrna, Inc, | Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof |
| EP2121924A1 (en) | 2007-03-02 | 2009-11-25 | MDRNA, Inc. | Nucleic acid compounds for inhibiting vegf family gene expression and uses thereof |
| WO2008137758A2 (en) | 2007-05-04 | 2008-11-13 | Mdrna, Inc. | Amino acid lipids and uses thereof |
| JP5296328B2 (ja) | 2007-05-09 | 2013-09-25 | 独立行政法人理化学研究所 | １本鎖環状ｒｎａおよびその製造方法 |
| DK2217062T3 (en) * | 2007-11-06 | 2015-08-24 | Sirnaomics Inc | MULTI-TARGET READY RNAi therapeutics TO ARFRI WOUND HEALING OF SKIN |
| UA97559C2 (uk) | 2007-11-08 | 2012-02-27 | Оцука Фармасьютікал Ко., Лтд. | Комплекс нуклеїнової кислоти і композиція для доставки нуклеїнової кислоти |
| CA2710713C (en) * | 2007-12-27 | 2017-09-19 | Protiva Biotherapeutics, Inc. | Silencing of polo-like kinase expression using interfering rna |
| US8188060B2 (en) * | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
| CA2719963A1 (en) | 2008-03-31 | 2009-10-08 | National Institute Of Advanced Industrial Science And Technology | Double-stranded lipid-modified rna having high rna interference effect |
| WO2011119887A1 (en) | 2010-03-24 | 2011-09-29 | Rxi Pharmaceuticals Corporation | Rna interference in dermal and fibrotic indications |
| EP2550001B1 (en) * | 2010-03-24 | 2019-05-22 | Phio Pharmaceuticals Corp. | Rna interference in ocular indications |
| AR083445A1 (es) | 2010-10-14 | 2013-02-27 | Univ Mie | siARN CONTRA LA FIBROSIS |
-
2011
- 2011-10-13 AR ARP110103808A patent/AR083445A1/es unknown
- 2011-10-14 MX MX2013003698A patent/MX348555B/es active IP Right Grant
- 2011-10-14 PL PL11832611T patent/PL2628798T3/pl unknown
- 2011-10-14 BR BR112013006541A patent/BR112013006541A2/pt not_active IP Right Cessation
- 2011-10-14 LT LTEP11832611.5T patent/LT2628798T/lt unknown
- 2011-10-14 EP EP11832611.5A patent/EP2628798B1/en not_active Not-in-force
- 2011-10-14 KR KR1020137007962A patent/KR101853799B1/ko active IP Right Grant
- 2011-10-14 KR KR1020187011751A patent/KR102167225B1/ko active IP Right Grant
- 2011-10-14 ES ES11832611T patent/ES2720135T3/es active Active
- 2011-10-14 AU AU2011314653A patent/AU2011314653B2/en not_active Ceased
- 2011-10-14 TW TW105110662A patent/TWI679023B/zh not_active IP Right Cessation
- 2011-10-14 RU RU2013121802/10A patent/RU2583290C2/ru active
- 2011-10-14 EP EP19158202.2A patent/EP3517614A1/en not_active Withdrawn
- 2011-10-14 SG SG2013024757A patent/SG189245A1/en unknown
- 2011-10-14 SG SG10201907649QA patent/SG10201907649QA/en unknown
- 2011-10-14 CN CN201610411134.1A patent/CN106086022B/zh not_active Expired - Fee Related
- 2011-10-14 PT PT11832611T patent/PT2628798T/pt unknown
- 2011-10-14 WO PCT/JP2011/073628 patent/WO2012050181A1/ja active Application Filing
- 2011-10-14 TR TR2019/05060T patent/TR201905060T4/tr unknown
- 2011-10-14 HU HUE11832611A patent/HUE043891T2/hu unknown
- 2011-10-14 NZ NZ609440A patent/NZ609440A/en not_active IP Right Cessation
- 2011-10-14 SI SI201131728T patent/SI2628798T1/sl unknown
- 2011-10-14 US US13/824,080 patent/US8772262B2/en not_active Expired - Fee Related
- 2011-10-14 CA CA2813163A patent/CA2813163C/en not_active Expired - Fee Related
- 2011-10-14 MY MYPI2013000567A patent/MY165964A/en unknown
- 2011-10-14 DK DK11832611.5T patent/DK2628798T3/da active
- 2011-10-14 TW TW100137418A patent/TWI572715B/zh not_active IP Right Cessation
- 2011-10-14 CN CN201180044862.9A patent/CN103119166B/zh not_active Expired - Fee Related
- 2011-10-14 JP JP2012538721A patent/JP6022940B2/ja not_active Expired - Fee Related
- 2011-10-14 NZ NZ630501A patent/NZ630501A/en not_active IP Right Cessation
- 2011-10-14 SG SG10201508365RA patent/SG10201508365RA/en unknown
-
2013
- 2013-02-18 IL IL224791A patent/IL224791A/en active IP Right Grant
- 2013-02-19 ZA ZA2013/01279A patent/ZA201301279B/en unknown
- 2013-04-11 CO CO13094380A patent/CO6660456A2/es unknown
- 2013-10-15 HK HK13111550.4A patent/HK1184189A1/zh not_active IP Right Cessation
-
2014
- 2014-05-08 US US14/272,898 patent/US9273314B2/en not_active Expired - Fee Related
-
2016
- 2016-01-19 US US15/000,204 patent/US9637743B2/en active Active
- 2016-06-02 IL IL245995A patent/IL245995B/en active IP Right Grant
- 2016-07-19 JP JP2016141580A patent/JP2017000155A/ja active Pending
-
2017
- 2017-03-22 US US15/465,961 patent/US10125366B2/en not_active Expired - Fee Related
- 2017-12-27 JP JP2017250450A patent/JP2018088923A/ja active Pending
-
2018
- 2018-09-24 US US16/139,461 patent/US20190010500A1/en not_active Abandoned
-
2019
- 2019-04-17 HR HRP20190722TT patent/HRP20190722T1/hr unknown
- 2019-06-20 CY CY20191100643T patent/CY1121945T1/el unknown
- 2019-08-01 US US16/528,920 patent/US20200291406A1/en not_active Abandoned
-
2020
- 2020-01-28 JP JP2020011342A patent/JP2020078314A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013026494A2 (pt) | composto, composição farmacêutica, método para tratar condição | |
| WO2015106128A3 (en) | Rnai agents modified at the 4'-c-position | |
| WO2018115527A3 (en) | Mers coronavirus vaccine | |
| MX2024005653A (es) | Agentes de acido ribonucleico (arn) de cadena doble modificados. | |
| EP3862362A3 (en) | Conjugates of modified antisense oligonucleotides and their use for modulating pkk expression | |
| MX2022005200A (es) | Composiciones y metodos para modular la expresion de angiotensinogeno. | |
| PE20090064A1 (es) | Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende | |
| BR112018010650A8 (pt) | pró-fármacos de um inibidor de jak composto para o tratamento da doença inflamatória gastrointestinal | |
| MX359548B (es) | Agentes de iarn modificados. | |
| TR201818825T4 (tr) | Kardi̇yak hi̇pertrofi̇ni̇n tedavi̇si̇ne ve tanisina yöneli̇k lncrnalar | |
| MX2021006745A (es) | Constructos de iarn modificados quimicamente y usos de estos. | |
| EP2493464A4 (en) | METHYLSULFONYLMETHANE (MSM) FOR THE TREATMENT OF DRUG-RESISTANT MICROORGANISMS | |
| PE20142404A1 (es) | Compuestos de microarn y metodos de modulacion de la actividad de mir-21 | |
| CL2011002460A1 (es) | Torta liofilizada que comprende un inhibidor de proteasoma derivado del acido protonico, una ciclodextrina, y al menos un agente espesante y/o un surfactante; metodo para su fabricacion; y su uso en el tratamiento de mieloma multiple. | |
| PE20140255A1 (es) | Tableta dispersable en forma oral | |
| MX354940B (es) | Oligonucleotidos funcionalmente modificados y subunidades de los mismos. | |
| SG10201809290SA (en) | Compositions and Methods to Treating Hemoglobinopathies | |
| EA201490563A1 (ru) | Антисмысловые олигонуклеотиды для лечения врожденного амавроза лебера | |
| AR084319A1 (es) | INHIBIDORES DE microARN (miARN O miR) QUE COMPRENDEN NUCLEOTIDOS BLOQUEADOS | |
| HN2012000023A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| PE20121495A1 (es) | Combinacion de un agente quimioterapeutico y un inhibidor del sistema tgf-beta | |
| CO6660456A2 (es) | Agente preventivo o terpéutico contra la fibrosis | |
| CR20160433A (es) | Nuevos compuestos | |
| CO2019010062A2 (es) | Novedoso bacteriófago clo-pep-2 de clostridium perfringens y su uso para inhibir la proliferación de clostridium perfringens | |
| CL2016002879A1 (es) | Composiciones farmacéuticas para tratar enfermedades infecciosas |